<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888351</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0145</org_study_id>
    <nct_id>NCT04888351</nct_id>
  </id_info>
  <brief_title>Immediate Breast Reconstruction's Increasing</brief_title>
  <acronym>IBRI</acronym>
  <official_title>Mastectomy and Breast Cancer : Follow-up of IBR's Rate and Study of Complications as Compared to Delayed Reconstructions Between 2016 and 2020 in Lyon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mastectomy in breast cancer is still a way of treatment. Nowadays, the goal is to improve&#xD;
      reconstruction's technicals. Immediate Breast Reconstruction (IBR) is one of them, largely&#xD;
      used in United States but less in France. However, IGR (Insitut Gustave Roussey) in Paris&#xD;
      just wrote a new protocole wich allows more IBR by including more patients.&#xD;
&#xD;
      This study aims to compare complications in 2 groups: mastectomies followed by IBR and&#xD;
      mastectomies without IBR. The second goal will try to estimate the proportion of eligible's&#xD;
      patients to IBR, and to analyse their surgicals and oncologicals risk factors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global complications's rates in 2 groups (percentage)</measure>
    <time_frame>During first year after surgery</time_frame>
    <description>Comparison of complications between mastectomies with IBR and mastectomies without IBR</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Breast Reconstruction</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Mastectomies with IBR</arm_group_label>
    <description>Every women&gt;18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mastectomies without IBR</arm_group_label>
    <description>Every women&gt;18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparison of complications between mastectomies with IBR and mastectomies without IBR</intervention_name>
    <description>Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.&#xD;
Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain.</description>
    <arm_group_label>Mastectomies with IBR</arm_group_label>
    <arm_group_label>Mastectomies without IBR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>To analyze variations of number of patients eligibles to IBR</intervention_name>
    <description>Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past</description>
    <arm_group_label>Mastectomies with IBR</arm_group_label>
    <arm_group_label>Mastectomies without IBR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients aged 18 or more, who have had a mastectomy for breast cancer in&#xD;
        Croix-Rousse's hospital in Lyon, between 1st of January 2016 and 31st of December 2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years&#xD;
&#xD;
          -  Breast cancer&#xD;
&#xD;
          -  Mastectomy&#xD;
&#xD;
          -  Hopital de la Croix-Rousse&#xD;
&#xD;
          -  January 2016 and January 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prophylactic mastectomy&#xD;
&#xD;
          -  Male gender&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion CORTET, MD</last_name>
    <phone>4 27 85 40 78</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.cortet@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion CORTET, MD</last_name>
      <phone>4 27 85 40 78</phone>
      <phone_ext>+33</phone_ext>
      <email>marion.cortet@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immediate Breast Reconstruction (IBR)</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

